Reply to J. Bergquist et al and T.-Y. Lai et al

Journal of Clinical Oncology

Volumn 35, Issue 14, 2017, Pages 1624-1625

  Mokdad, Ali A ^a   Minter, Rebecca M ^a   Zhu, Hong ^a   Mansour, John C ^a   Choti, Michael A ^a   Polanco, Patricio M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN;

CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; EARLY CANCER; HUMAN; INTENTION TO TREAT ANALYSIS; LETTER; MEDIAN SURVIVAL TIME; OVERALL SURVIVAL; PANCREAS CANCER; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPENSITY SCORE; SYSTEMIC THERAPY; NEOADJUVANT THERAPY; PANCREAS TUMOR;

HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PROPENSITY SCORE;

EID: 85019064468     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.3891     Document Type: Letter

References (10)

1. Mokdad AA, Minter RM, Zhu H, et al: Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: A propensity score matched analysis. J Clin Oncol 35:515-522, 2017
2. Bergquist JR, Shubert CR, Storlie CB, et al: Patient selection for neoadjuvant therapy in early-stage pancreatic cancer. J Clin Oncol 35:1622-1623, 2017
3. Shubert CR, Bergquist JR, Groeschl RT, et al: Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database. Surgery 160:1080-1096, 2016
4. Hartwig W, Hackert T, Hinz U, et al: Pancreatic cancer surgery in the new millennium: Better prediction of outcome. Ann Surg 254:311-319, 2011
5. Humphris JL, Chang DK, Johns AL, et al: The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 23:1713-1722, 2012
6. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763, 1997
7. Lachin JM: Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 2:93-113, 1981
8. Lai T-Y, Hu Y-W: Neoadjuvant therapy in resectable pancreatic cancer: Immortal time bias and its correction. J Clin Oncol 35:1623, 2017
9. Giobbie-Hurder A, Gelber RD, Regan MM: Challenges of guarantee-time bias. J Clin Oncol 31:2963-2969, 2013
10. Shariff SZ, Cuerden MS, Jain AK, et al: The secret of immortal time bias in epidemiologic studies. J Am Soc Nephrol 19:841-843, 2008